REGEN-COV lowers risk of COVID-19 hospital stay, death by 71%

Regeneron's combination of two monoclonal antibodies lowered the risk of COVID-19–associated hospitalization and death from any cause by 71% and resolved symptoms and reduced SARS-CoV-2 viral load faster than a placebo, a phase 3 clinical trial finds.

In the study, published yesterday in the New England Journal of Medicine, a team led by Regeneron researchers randomly assigned 2,696 adult COVID-19 outpatients at high risk for severe illness to receive either intravenous REGEN-COV or a placebo from Sep 24, 2020, to Jan 17, 2021.

REGEN-COV is a 1:1 combination of the monoclonal antibodies casirivimab and imdevimab.

Effective regardless of baseline antibody status

Of 1,355 patients given 2,400 milligrams (mg) of REGEN-COV, 18 (1.3%) were hospitalized or died from any cause within 28 days, compared with 62 of 1,341 patients (4.6%) given placebo (relative risk reduction [RRR], 71.3%).

Seven of 736 patients (1.0%) who received 1,200 mg of REGEN-COV were hospitalized or died, versus 24 of 748 (3.2%) of the placebo group (RRR, 70.4%). The REGEN-COV group was also less likely to require intensive care unit admission.

The researchers noted that previous research has shown that REGEN-COV is effective in vitro against variants of concern, including Delta (B1617.2).

Patients given placebo who had SARS-CoV-2 antibodies at the start of the trial had a comparable incidence of hospitalization and death as those who had no antibodies, suggesting that some patients with antibodies mounted an ineffective immune response.

"Moreover, this trial showed that REGEN-COV is associated with clinical benefit, regardless of baseline serum antibody status, so that serologic testing at the time of the COVID-19 diagnosis is less critical for making clinical treatment decisions," the study authors wrote.

Faster symptom resolution, lower viral load

Symptoms in the REGEN-COV group resolved a median of 4 days faster than in the placebo group, regardless of dose (10 vs 14 days). Both doses of REGEN-COV also lowered viral load faster than placebo.

The placebo group experienced more serious adverse events (4.0%) than the 1,200-mg REGEN-COV group (1.1%) and the 2,400-mg group (1.3%). Less than 0.3% of patients in all groups had a moderate or severe infusion-related adverse reaction.

Median patient age was 50 years, 14% were 65 and older, 49% were men, 35% were Hispanic, and most had experienced symptoms for 3 days before study enrollment. The most common risk factors included obesity (58%), age 50 and older (52%), and cardiovascular disease (36%), and 3% were immunocompromised. Most (69%) had no SARS-CoV-2 antibodies at baseline, and the median viral load was high, suggesting the early phase of infection.

The phase 1/2 trial showed that the drug reduced both SARS-CoV-2 viral load and the number of medical visits and that 2,400-milligram (mg) and 8,000-mg doses had comparable antiviral and clinical efficacy.

In November 2020 the US Food and Drug Administration granted emergency use authorization to REGEN-COV for treating high-risk patients 12 and older who have moderate to severe COVID-19. The authorization was expanded for post-exposure prophylaxis in July 2021. The drug is free for eligible patients.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»


Unrestricted financial support provided by

Bentson Foundation Unorthodox Philanthropy logo and text 'Leading Underwriter'3M logoGilead 
Grant support for ASP provided by


  Become an underwriter»